文献速递临床试验与 GCP新药、器械与细胞基因治疗研发

康莱特注射液联合一线化疗对比单纯一线化疗治疗晚期非小细胞肺癌:一项研究者发起的多中心开放标签随机对照试验研究方案

Combination of first-line chemotherapy with Kanglaite injections versus first-line chemotherapy alone for advanced non-small-cell lung cancer: study protocol for an investigator-initiated, multicenter, open-label, randomized controlled trial.
PubMed 文献 · Trials · 2021-03-17

本研究为研究者发起的多中心开放标签随机对照试验,计划纳入334例IIIA-IV期非小细胞肺癌患者,1:1随机分为康莱特注射液联合一线含铂双药化疗组与单纯化疗组,主要终点为无进展生存期,旨在评估联合治疗的长期疗效与安全性。

要点

  • 康莱特注射液联合一线化疗可能改善晚期NSCLC的短期疗效、生活质量和体力状况。
  • 本试验以无进展生存期为主要终点,首次评估康莱特联合化疗的长期疗效与安全性。
  • 康莱特注射液用法为化疗首日起每日静脉滴注200 ml,连续14天。

核心结论

  • 本试验旨在评估康莱特注射液联合一线化疗对比单纯化疗治疗晚期非小细胞肺癌的长期疗效与安全性。

研究设计与样本

  • 研究者发起的多中心、开放标签、随机对照试验,计划随机分配334例IIIA-IV期NSCLC患者,1:1分为治疗组和对照组。

主要发现

  • 原文未报告研究结果,本方案主要终点为无进展生存期,次要终点包括客观缓解率、1年生存率、生活质量、生活能力和血脂,安全性终点为不良事件发生率。

关键数值与推荐

  • 治疗组在化疗首日起每日静脉给予康莱特注射液200 ml,连续14天,直至疾病进展或出现不可接受的毒性。
  • 两组均接受4-6周期一线含铂双药化疗,达到完全缓解、部分缓解或疾病稳定的患者后续接受非铂单药化疗。
  • 随访每2个月一次,直至死亡、失访或随机入组后12个月。

临床怎么用

  • 该方案为康莱特注射液联合一线化疗在晚期NSCLC中的应用提供长期疗效与安全性证据。

局限性

  • 本文件为研究方案,尚无结果数据;开放标签设计可能引入偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Non-small-cell lung cancer (NSCLC) is usually diagnosed at an advanced stage, and chemotherapy is the main treatment for this disease. Kanglaite injections (KLTi) have been widely used for the treatment of cancer in China. KLTi combined with chemotherapy could improve the short-term efficacy, quality of life, and performance status for NSCLC compared with chemotherapy alone. This trial aims to assess the long-term efficacy and safety of KLTi in combination with chemotherapy for the treatment of advanced NSCLC. METHODS: This will be an investigator-initiated multicenter open-label randomized controlled trial. We will randomly assign 334 eligible participants with stage IIIA-IV NSCLC to the treatment or control groups in a 1:1 ratio. Patients in both groups will be administered 4-6 cycles of first-line platinum-based double chemotherapy regimens. Patients with complete response, partial response, or stable disease after 4-6 cycles will receive non-platinum single-agent chemotherapy. Patients in the treatment group are to receive intravenous KLTi 200 ml per day continuously for 14 days, commencing on the first day of chemotherapy. The treatment will be discontinued at the time of disease progression or until unacceptable toxicity is noted. The follow-up will be conducted every 2 months until death, loss of follow-up, or 12 months from randomized enrollment. The primary outcome will be progression-free survival (PFS). The secondary outcomes will be the objective response rate, 1-year survival rate, quality of life, living ability, and blood lipids. The safety outcome will be the rate of adverse events. DISCUSSION: This study will be the first randomized controlled trial in which PFS is used as the primary outcome to test whether KLTi combined with first-line chemotherapy has superior efficacy and reduced toxicity compared to chemotherapy alone in advanced NSCLC. This will also be the first clinical study to observe the effects of KLTi on blood lipids. TRIAL REGISTRATION: ClinicalTrials.gov NCT03986528 . Prospectively registered on 30 May 2019.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Gao R, Zhang Y, Hou W, et al. Combination of first-line chemotherapy with Kanglaite injections versus first-line chemotherapy alone for advanced non-small-cell lung cancer: study protocol for an investigator-initiated, multicenter, open-label, randomized controlled trial. Trials. 2021. PMID: 33731199. doi:10.1186/s13063-021-05169-w

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。